The company also said it reduced its low-carbon spending target to $20 billion from $30 billion through 2030.
Test your knowledge—and read our latest stories for a little extra help.
Nuvalent, Inc. , a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback